Effect of lurasidone plus sulpiride on treatment efficacy, psychiatric manifestations, and quality of life among patients with schizophrenia

Figure 1 Quality of life evaluation of the two patient groups. A: Pre-treatment and post-treatment psychosocial scores of the two groups; B: Pre-treatment and post-treatment symptoms and side effect scores of the two groups; C: Pre-treatment and post-treatment motivation and energy scores of the two groups. ^aP < 0.05 and ^bP < 0.01 vs the pre-treatment levels; ^cP < 0.05 vs control.

Figure 2 Serum markers of the two patient groups. A: Pre-treatment and post-treatment interleukin 6 (IL-6) levels; B: Pre-treatment and post-treatment IL-17 Levels; C: Pre-treatment and post-treatment prolactin levels. PRL: Prolactin. ^aP < 0.05 and ^bP < 0.01 vs the pre-treatment levels; ^cP < 0.05 vs control.